Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06897969

Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Keloid Scars Cicatrix Collagen Diseases Connective Tissue Diseases Fibrosis Keloid Pathologic Processes Pathological Conditions, Signs and Symptoms Skin and Connective Tissue Diseases

Age range

10 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Nishtar Medical University & Hospital

Multan, Punjab Province, 60000, Pakistan

Location contact

Dr. Asma Batool, MBBS

CONTACT

[email protected]

0923470416435

Dr. Asma Batool, MBBS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • size of keloid1-5 cm,
  • on any site of the body,
  • duration less then five years and
  • baseline Vancouver scar score of more the or equal to 5

Exclusion criteria

  • Pregnant or lactating women,
  • family history of keloids,
  • acromegaly, and
  • congestive cardiac diseases

Treatment and study plan

Triamcinolone Acetonide 1 ml of 40 mg/mL suspension

Drug

Monthly intralesional injection

Verapamil Injection

Drug

2.5 mg of intralesional Verapamil injection monthly

Primary outcomes

  1. Change in Vancouver Scar Score

    Time frame: Vancouver Scar score will be measured at baseline (before treatment assignment) and then 4-weeks after completion of treatment - 16-weeks after randomization.

    The Vancouver Scar scale assesses four parameters of vascularity, pigmentation, pliability and height. The total score ranges from 0 - 13.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Asma Batool, MBBS

CONTACT

[email protected]

923470416435

Sponsors and collaborators

Lead sponsor

Nishtar Medical University

Other

Registry information

Official study title

Comparison of Intralesional Triamcinolone and Intralesional Verapamil in the Treatment of Keloids

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 27, 2025
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.